| 1. |
European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42. |
| |
|
| 2. |
Alberti A, Caporaso N. HBV therapy: guidelines and open issues. Dig Liver Dis. 2011 Jan;43 Suppl 1:S57-63. |
| |
|
| 3. |
Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011 Jan;31 Suppl 1:111-6. |
| |
|
| 4. |
Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422-30. |
| |
|
| 5. |
Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2010 Nov 18 [Epub ahead of print]. |
| |
|
| 6. |
Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218-29. |
| |
|
| 7. |
Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13(8):934-45. |
